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ABSTRACT
Background 
In the normal kidney, the glomerular filtration barrier successfully clears about one litre 
blood per minute. Damage to the filtration barrier might lead to protein leakage in the 
urine – proteinuria. The major ultra-structural finding in glomerular diseases with 
proteinuria is foot process effacement (FPE). Despite these being the most common 
signs of glomerular dysfunction, the underlying pathophysiological mechanisms are 
still not fully understood. However, a number of proteins identified in the slit 
diaphragm (SD) of the podocytes, including Dendrin and Neph1, are believed to be 
significant. Dendrin is a protein that has previously been described in mouse podocytes, 
associated to the actin cytoskeleton. Neph1 is a transmembrane protein that forms a 
complex with Nephrin in the SD. Recent studies have indicated the complex 
involvement in polymerization of the actin cytoskeleton and proteinuria. 
 
Aim 
We aimed to study the expression of Dendrin in normal human kidney and in the 
glomerular disease Minimal Change Nephrotic Syndrome (MCNS) with proteinuria and 
foot process effacement (FPE). In the second study, we wanted to investigate the 
subcellular localization of Neph1 in normal human kidney and the expression in Focal 
Segmental Glomerulosclerosis (FSGS), MCNS and in the corresponding experimental 
models Adriamycin nephropathy (ADR) and puromycin aminonucleoside (PAN). All 
characterized by substantial FPE and proteinuria. 
Methods 
The localization of Dendrin and Neph1 was first studied in normal kidney tissue and 
then compared to the expression in biopsy specimens of the above mentioned diseases, 
using light and electron microscopy. The expression was semiquantified by immuno-
electron microscopy (iEM).   
 
Results 
Dendrin was localized solely in the podocytes close to the SD. There was no significant 
change in the total amount of Dendrin in MCNS compared to controls by 
immunofluorescence and iEM. Neph1 was also localized mainly to the SD. Double 
staining of Neph-1 and Nephrin showed the proteins in close connection in the SD. The 
total amount of Neph1 was significantly reduced in the glomerular diseases FSGS, 
MCNS and in ADR and PAN. The reduction of Neph1 was also seen in areas without 
FPE. Nephrin was reduced in MCNS and PAN but unchanged in FSGS.  
Conclusion 
In preserved slits and in areas without FPE in MCNS, the amounts of Dendrin were 
unchanged compared to controls. The redistribution might therefore be secondary to 
FPE. Neph1 co-localize with Nephrin in the SD and was reduced in FSGS, MCNS, 
ADR and PAN. Nephrin was however, unchanged in FSGS which could indicate a 
disruption of the Neph1-Nephrin complex and an involvement of Neph1 in the 
pathogenesis of this disease. 
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3 LIST OF ABBREVIATIONS 
 
 
BSA= Bovine Serum Albumin 
 
FPE= Foot Process Effacement  
 
FSGS= Focal Segmental Glomerulosclerosis 
 
GBM= Glomerular Basement Membrane 
 
iEM= Immuno Electron Microscopy 
 
IFL= Immunofluorescence 
 
MCNS= Minimal Change Nephrotic Syndrome 
 
PB= Phosphate buffer 
 
PAS= Periodic-Acid Sciff 
 
PASM= Periodic Acid Silver  
 
SD= Slit Diaphragm 
 
TEM= Transmission Electron Microscopy 
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4 BACKGROUND
 
 
4.1 THE NORMAL KIDNEY 
 
4.1.1 Structure
Structurally the kidney is composed of an outer cortex and an inner medulla (Figure 1). 
The kidneys functional units are called nephron. A normal human kidney has 
approximately 1 million nephrons consisting of a glomerulus and a tubular system 
(Figure 2). The glomerulus consists of small capillary bundles, held together by 
mesangial cells and their matrix, all encapsulated by Bowmans capsule (Figure 3-5) 
which is connected to the tubular system. 
.  
Figure 1. The normal human kidney. Copyright © 2001, Rights Managed by Nature Publishing Group. 
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Figure 2. Parts of the nephron.  Copyright ©, Rights Managed by unckidneycenter.org 
 
 
Figure 3. The glomerular filtration. Copyright © 2009, Rights Managed by Nature Publishing Group.  
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Figure 4a. Light microscopy image of normal glomeruli. Figure 4b. Light microscopy image of 
normal glomerulus. 
 
 
 
 
Figure 5. Electron microscopy image of a normal glomerulus. C= capillaries, M=mesangium. 
 
 
 
4.1.2 Function
 
The main function of the kidney is to clear the blood from waste products. This is 
performed in the glomerulus. Blood enters the glomerulus via the afferent (inward) 
arteriole. When the blood has been filtered it leaves the glomerulus through the efferent 
(outgoing) arteriole (Figure 3). The filtration product, the primary urine, is normally 
free from proteins and blood cells and measures about 180 l/day. Most of this liquid 
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will be reabsorbed in the tubular system and the amount of urine will be about 1.5 l / 
day. 
 
4.1.3 Filtration 
 
The filtration barrier of the glomerular capillaries consists of three layers; the 
endothelium, the glomerular basement membrane (GBM) and the podocytes (Figure  
6b, 7). Components of low molecular weight and small size, such as water, urea and 
glucose pass through the filtration barrier unhindered. Albumin, with its molecular 
weight of 69kDa, do not pass under normal, healthy conditions. The primary urine is 
collected in the Bowman´s capsule and will then continue through the tubular system. 
The first layer, the fenestred endothelium has a negatively charged cell surface 
glycocalyx, containing proteoglycans and sialo proteins. It has not historically been 
considered central to the glomerular perm-selectivity, but growing evidence suggests 
otherwise (1). 
The mayor components of the second layer, the 300-350 nm GBM, are type-ІV 
collagen, negatively charged proteoglycanes, laminin, nidogen and positively charged 
heparan sulphate. The GBM has been described as the charge-selective barrier for 
glomerular filtration. This is now questioned by studies on the selective removal of 
highly anionic substances, which appears to neither influence the glomerular charge 
selectivity nor increase the degree of proteinuria (2).  
The outer layer of the capillary wall consists of podocytes with cell bodies and foot 
processes (Figure 6b). The foot processes are connected by slit diaphragms (SD) 
(Figure 6c). 
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Figure 6. The glomerular capillaries, podocytes and slit diaphragm. Copyright © 2009, Oxford 
University Press. 
 
 15 
 
 
Figure 7. Electron microscopy image of the glomerular filtration barrier. E= endothelium, 
GBM= glomerular basement membrane, P= podocytes. 
 
 
 
4.1.4 The podocyte 
 
The podocyte is a terminally differentiated epithelial cell, which means that damaged is 
irreversible. This highy specialized cell consists of  a cell body, main processes and 
foot processes. The cell body and the main processes both consists primarily of 
microtubules and intermediate filaments. The foot processes contain longitudinal actin 
microfilaments and are anchored to the underlying basement membrane via integrins 
and dystroglycans. The podocytes both retain the structure of GBM and produce many 
of its components, for example heparan sulphate proteoglycans. Damage to the 
podocytes disturbs this symbiosis. A thickening of the GBM due to the podocytes 
increased production of matrix protein is seen in the glomerular disease Membranous 
Nephropathy (MN). The podocytes also affect the endothelial cells by production of 
vascular endothelial growth factor (VEGF) and angiopoetin which act in a paracrine 
manner on the endothelium (3). 
 
 
4.1.5 The slit diaphragm 
As described above, the foot processes of the podocytes are connected via slit 
diaphragms, a 25-60 nm wide filtration slit with signaling properties (Figure 6c, 7). 
Their morphological structure resembles desmosomes and adherens junctions. The 
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slit diaphragm as a structure was first described by Karnovsky in 1974 in mice and 
rats (4) and then, the following year in humans (5). 
In 1998 Tryggvason et al. identified the protein Nephrin as a major component of the 
SD. By positional cloning, a mutation in its encoding gene, NPHS1, could be linked 
to congenital nephrosis of the Finish type (6), a condition characterized by heavy 
proteinuria in utero. This led to a new interest in the slit diaphragm and their role in 
glomerular diseases. Since the discovery of Nephrin, numerous new proteins have 
been identified in the area. It is now recognized that the SD proteins, for example 
Nephrin (6), P-cadherin (7), Neph1 (8) and FAT (9), are linked to the foot process 
actin-based cytoskeleton by adaptor proteins (10), such as CD2-associated protein 
(CD2AP) (11, 12), Zonula Occludens (ZO-1) (13), podocin (14), (Figure 6c) and 
through the signaling pathways thereby maintain the structure and function of the 
podocytes (10). The Tryggvason group has in collaboration with our group continued 
the search for important structural proteins by the usage of knock down zebra fishes 
and knock out mice. The effect on the glomerular filtration barrier is studied with 
functional tests, light - and electron microscopy (EM) and whether proteinuria is a 
result of the specific protein being missing or not. Antibodies against the proteins are 
raised and used to localize the proteins, both by immunofluorescence (IFL) and on a 
subcellular level in human material by EM.  
 
4.2 PATHOLOGY
Approximately 1 million of the Swedish population suffers from impaired kidney 
function (15). Globally, the frequency is about 15% (16). Chronic kidney disease leads 
eventually to renal failure which requires dialysis or transplantation. About 25% of the 
cases of chronic kidney failure are due to glomerulonephritis (17). 
The therapies offered today are unspecific and sometimes even harmful. This is due to 
the limited knowledge of the mechanisms behind the pathogenesis of acquired 
glomerular diseases. 
 
 
4.2.1 Proteinuria and foot process effacement
 
The most common sign of renal disease and glomerular dysfunction is proteinuria, 
leakage of proteins, in the urine. This is in itself harmful to the kidney (18). Proteinuria 
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is caused by the dysfunction of the selective permeability through the filtration barrier, 
probably foremost affected by structural and functional defects of the podocytes. 
The combination of pronounced proteinuria (>3,5 g protein/24h), hypoalbuminuria 
oedema and hyperlipidemia is referred to as  nephrotic syndrome. 
A characteristic ultrastructural finding in nephrotic syndrome and proteinuric diseases 
is so called foot process effacement (FPE) as first described by Farquar in 1957 (19). 
This shortening and widening of the foot processes is initiated by the re-arrangement of 
the parallel actin filaments of the cytoskeleton into a compressed network (Figure 8b). 
However, proteinuria can occur without FPE, and the degree of FPE does not correlate 
to the amount of proteinuria (20). The underlying cause of  FPE is still extensively 
discussed, as to whether this morphological feature is due to podocytic injury by toxins 
or infections, a result of protein and/or signaling defects in the SD or cytoskeleton, or 
altogether secondary to proteinuria.  
Indeed, there are several mutations in podocyte-associated proteins identified in 
hereditary proteinuria, such as CD2AP (11), α-actinin-4 (21), TRPC6 (22) and podocin 
(23), but it is commonly accepted that proteinuria should not be thought of  only as a 
defect of the podocyte, but rather as a defect of the filtration barrier as a whole, with the 
lesion in any compartment (3).  It is still, however, an open question whether 
proteinuria precedes FPE or the other way around.  Shankland lists the three general 
views in his 2006 review (24): 
1. Effacement in itself causes proteinuria, through a decrease of the number of slit 
diaphragms along the GBM.
2. Effacement is the result of podocytic injury or abnormality that also leads to 
proteinuria, but it is not the cause. 
3. Effacement and proteinuria are altogether independent of each other. 
Shankland places his own vote somewhere in between those. 
The following scenarios behind FPE and proteinuria have been singled out by recent 
podocyte studies, and summarized by Tae-Sun Ha´s 2013 review (25), as:  
1. Interference with the SD complex.  
2. Interference with the GBM or the podocyte-GBM interaction. 
3. Interference with the actin cytoskeleton and its proteins. 
4. Interference with the negative apical membrane domain of podocytes. 
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Figure 8a. Electron microscopy image of normal glomerular capillaries. Figure 8b. 
Electron microscopy image of foot process effacement in MCNS. 
 
 
4.2.2 Focal Segmental Glomerulosclerosis (FSGS) 
One of the most common causes of nephrotic syndrome and a significant cause of 
chronic renal failure is focal segmental glomerulosclerosis (FSGS). The disease 
manifests with proteinuria, glomerular lesions of focal and segmental sclerosis and FPE 
(Figure 9). FSGS can be of either primary or secondary type. Secondary FSGS have an 
underlying cause such as virus-or drug-association, heritability or can be mediated by 
adaptive structural-functional responses, such as renal dysplasia or obesity. 
The disease is primary a histological diagnosis, based on the presence of segmental 
sclerotic lesions involving some, but not all glomeruli. Ever since the first portrayals of 
the disease by Fahr and Rich in 1925 and 1957 respectively, several different types of 
FSGS have been described (26-28) and numerous attempts of classification have been 
made. According to the pathologic classification system of Colombia (29, 30), FSGS 
include five different subclasses based on histological features; cellular, tip lesion, 
perihilar, collapsing and not otherwise specified (NOS). Based on this classification 
system, the perihilar type is characterised by sclerosis and/or hyalinosis in the perihilar 
region of the glomerulus.  
The significance of distinguishing between these histological types of FSGS clinically 
has been debated, but the FSGS studies of Thomas and Deegens, and most recently of 
D´Agati (31, 32, 33) have demonstrated considerable differences in both clinical 
features and renal outcome between the histological types.  
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Recent studies have identified a number of key players in the hereditary form of FSGS, 
including α-actinin-4 (21, 34), podocin (35), CD2-associated protein (CD2AP) (36), 
and transient receptor potential channel 6 (TRPC6) (37, 38).          
 
 
 
Figure 9. Light microscopy image of FSGS. PAS staining of a glomerulus with a segmental 
sclerosis (Arrow).  
 
 
4.2.3 Minimal Change Nephrotic Syndrome (MCNS) 
 
MCNS shares its most prominent clinical manifestations with FSGS, such as severe 
FPE and proteinuria – however, with normal appearance in light microscopy, as 
opposed to the focal, segmental glomerulosclerosis that characterizes FSGS. Thereof 
the name Minimal Change Nephrotic Syndrome. The use of transmission electron 
microscopy (TEM) to identify FPE is therefore a helpful tool in analyzing biopsy 
material (Figure 8b). 
MCNS is the most common disease underlying nephrotic range proteinuria among 
children. A common belief is that the cause of the podocytic injury in the disease is an 
abnormal regulation of a T cell subset (39). In 2003, we presented reduced Nephrin 
expression in the podocytes of MCNS patients (40). 
 
4.2.4 Animal models for proteinuria 
Animal models are an indispensable tool for studying the mechanisms of proteinuria 
and the function of specific proteins of the filtration barrier. Above all, they enable 
studies of different stages of proteinuria and FPE, from the onset and early stages, to 
fully developed disease. Based upon the area of interest there are now a vast number of 
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different animal models available, for example Heymann’s nephritis with formation of 
in situ immune complex, models of hyperfiltration due to reduced number of nephrons 
and the neutralization of the podocytes glycocalyx that results in FPE (41). We have 
used two non-transgenic animal models of nephrotic syndrome, puromycin 
aminonucleoside (PAN) administration to rats, and adriamycin administration (ADR) 
to mice. The podocytes are injured by toxins in both models. Puromycin interrupts the 
ribosomal protein translation and adriamycin leads to DNA inserts, resulting in massive 
proteinuria. 
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5 AIM
 
A genomic-, proteomic-, and bioinformatic research program has been launched by 
groups at KI and KTH to characterize novel glomerular proteins of possible importance 
in human glomerular disease. By collaboration with these groups, we have access to 
antibodies raised against newly identified glomerular proteins. The specifically 
produced antibodies in combination with the biopsy material from the hospitals bio 
bank offers an unique possibility to study the expression of novel proteins in the renal 
filtration barrier and their role in the pathogenesis of human glomerular diseases. With 
the hypothesis that the molecular structure of the podocyte slit diaphragm is altered in 
proteinuric diseases with foot process effacement we aimed to determine the 
distribution and localization of cytoskeleton associated proteins. Thus, we chose to 
study the SD proteins Dendrin and Neph1, both of unknown function, in the normal 
kidney and their expression in acquired glomerular diseases.  
In the Dendrin study we used MCNS as disease material and in the Neph1 study we 
added FSGS in order to compare the protein expression in a glomerular disease which 
often leads to chronic renal failure, in contrast to MCNS which is reversible. 
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6 ETHICAL CONSIDERATIONS 
Normal renal tissue was taken from unaffected kidneys that had been surgically 
removed because of localized carcinoma.  
All biopsies were taken for diagnostic purposes and re-examined to confirm the 
diagnosis. The material is used in agreement with the local ethical board (Dnr 1395–
32/2005). 
All animal experiment were conducted according to Swedish animal research 
regulations and approved by the local Board of Ethics (D228/99, 1395-32/2005, 
S65/2001, S25/2002, S209/03 N250/11). 
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PRESENTATION OF THE STUDY 
 
This thesis is composed of two articles, one published and one submitted. 
 
The first study describes the cytosolic podocyte protein Dendrin, which has previously 
been identified in the brain and in mouse podocytes, associated to the actin 
cytoskeleton. As the regulation of the actin cytoskeleton architecture in the podocyte 
foot processes is of considerable interest in glomerular diseases with proteinuria and 
FPE we wanted to study the expression of Dendrin in MCNS. The expression of the 
protein Zona Occludens-1 (ZO-1), known to be localized close to the SD, was also 
included as a comparison. 
 
The second study focus on the transmembrane protein Neph1 that forms a complex 
with Nephrin in the SD. With recent publications (42, 43) indicating the Neph1-
Nephrin complex involvement in polymerization of the actin cytoskeleton and in 
proteinuria, we wanted to study the expression  of Neph1 and compare it to that of 
Nephrin in FSGS and MCNS, and in their corresponding experimental models 
Adriamycin Nephropathy (ADR) and Puromycin aminonucleoside (PAN)-induced 
nephrosis.  
 24 
 
7 METHODS AND MATERIAL 
 
 
7.1.1 Human, normal renal tissue 
 
Normal renal tissue was taken from the unaffected parts of kidneys surgically removed 
because of localized carcinoma. 
 
7.1.2 Patients 
 
Patients, who fulfilled the criteria for FSGS and MCNS clinically and 
histopathologically, were chosen for the studies. Classification of FSGS was performed 
according to the Columbia system (29, 30). We used the perihilar variant as it is the 
most common type of primary FSGS in the biopsy material from our area. 
Biopsy material 
All biopsies included in the studies were taken for diagnostic purposes. They were all 
re-examined to confirm the diagnosis. For the iEM studies biopsy material has been 
saved prospectively and embedded in a low-temperature resin (K11M). 
 
7.1.3 Adriamycin Nephropathy (ADR) 
 
ADR is a well-established experimental model used as an animal model of human 
FSGS (41). The administration of the toxin adriamycin leads to a progressive, chronic 
glomerular disease, characterized by proteinuria, segmental glomerulosclerosis, FPE 
and tubulointerstitial fibrosis. Formerly being a model based upon rats, Wang et al 
published a protocol for mice in 2000. The method has greatly enhanced the 
understanding of the processes underlying the progression of renal injury (44).  
In our material we measured extensive albuminuria day 7 after injection, along with 
partial FPE. By day 14 segmental sclerotic lesions were detected in the glomeruli from 
all animals except one. This material abled us to study the protein expression in the 
initial phase, as well as in fully developed disease with sclerotic lesions in the 
glomeruli. 
 
 25 
 
7.1.4 Puromycin aminonucleoside nephropathy (PAN) 
 
 Puromycin aminonucleoside is an antibiotic originating from the Streptomyces 
alboniger bacterium. Intravenous administration of the toxin results in proteinuria and 
FPE (45), but in contrast to ADR it does not give rise to segmental glomerular sclerosis 
until after 16 weeks, and is therefore used as an experimental model of  MCNS. 
In our material, partial FPE was seen by day 2 after injection, before the onset of 
proteinuria by day 4. By day 4 the FPE was widespread. No sclerotic lesions were 
present in the glomeruli (46). 
We used material from day 2 in order to study the protein expression before proteinuria 
and the material from day 4 with both proteinuria and FPE as a comparison to human 
MCNS. 
 
7.1.5 Primary antibodies 
 
In preparation of polyclonal antibodies, the specific protein is biochemically isolated 
and injected in the animal. The immune response from the B cells gives a large amount 
of antibodies directed towards different epitopes of the antigen, i.e. polyclonal 
antibodies.The lgG fraction is then usually filtered out for production. To produce 
monoclonal antibodies, one (1) specific B cell is isolated and cloned to produce 
antibodies directed against the same, specific, epitope. 
For immunohistochemistry (especially iEM) studies, polyclonal antibodies are 
preferred as the probability of one specific epitope, being exposed on the surface of the 
embedded tissue is very low. If the antibodies are directed against a number of 
epitopes, the probability of them binding the specific protein increases. 
 
 
7.2 TISSUE PREPARATION 
 
7.2.1 Tissue preparation for light microscopy 
 
Specimens were fixed in 4% phosphate buffered formaline, dehydrated and embedded 
in paraffin according to standard procedures. 1,5 µm sections were cut on a microtome, 
and stained with hematoxylin-eosin, periodic-acid Sciff (PAS), Ladewig trichrome, and 
periodic acid silver (PASM). 
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7.2.2 Immunofluorescence (IFL) 
 
An unfixed piece of a renal biopsy taken for diagnostic purposes is snap frozen. 5 µm 
thick cryosections are incubated with FITC-conjugated antibodies against lgG, lgA, 
lgM, fibrinogen, the light chains kappa and beta and the complement factors C3 and 
C1q. 
For our studies the cryosections were postfixed with cold acetone (−20°C) and blocked 
in 5% normal goat serum. Primary antibodies were incubated overnight at 4°C and the 
secondary fluorescent antibody for an hour in the dark, in room temperature. 
 
 
7.2.3 Immunoperoxidase staining 
 
2, 5 µm sections of paraffin-embedded tissue were pre-treated with tris-EDTA (Dako, 
Glostrup, Denmark) followed by 3% H2O2 in methanol. 10% milk was used as blocking 
for 30 minutes. The primary antibody, or normal lgG as negative control, was 
incubated overnight after which the HRP-conjugated secondary antibody (Envision 
TM, Dako, Glostrup, Denmark) was added for 30 minutes at room temperature and 
then visualized by the DAB/ H2O2 substrate. Nuclei were stained by hematoxylin. 
 
7.2.4 Tissue preparation for transmission electron microscopy 
 
Tissue were fixed in a buffered 2% glutaraldehyde, and post-fixed in osmium 
tetraoxide (OSO4) in order to enhance contrasts. After alcohol dehydration the specimen 
were embedded in a hard plastic resin to enable the ultrathin sectioning of 
approximately 40- 60nm. The specimen were then mounted on a grid and finally 
contrasted by adding the heavy metals, lead citrate and uranyl acetate. 
 
 
 3.2.4  Immuno Electron Microscopy 
Small pieces of tissue were dehydrated in methanol and embedded in Lowicryl K11M 
(Chemische Werke Lowi, GmbH, Waldkreiburg, Germany), a special plastic which 
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enables iEM. Ultrathin sections were mounted on carbon/formvar nickel grids and 
incubated in 2% bovine serum albumin (BSA) and 2% gelatin in 0.1 M phosphate 
buffer (PB) at  pH 7.4 followed by incubation overnight  with primary antibodies 
(Dendrin, Neph1 and Nephrin), diluted 1:100 and 1:50 respectively, in 0.1M PB 
containing 0.1% BSA and 0.1% gelatin (PBBG). Bound antibodies were detected by 
protein A conjugated with 10 nm colloidal gold (Biocell Laboratories Inc., Rancho 
Dominguez, CA, USA), diluted 1:100 in PBBG. 
In double staining of Neph1 and Nephrin, Nephrin was incubated overnight, followed 
by Neph1 for 3 hours. Secondary antibodies were conjugated with 5 nm and 10 nm 
gold particles respectively.  
 
 
7.2.5 Semiquantification of structural proteins by iEM 
The primary antibody is bound 1:1 by protein A molecules tagged with a gold particle 
which, due to its high density, allows visualisation by TEM. Protein A derives from 
Stafylococcus Aureus and is used because of its specificity against the lgGs Fc part. 
This specific binding both enables semiquantification and gives lower background than 
secondary antibodies which bind to multiple epitopes of lgG. 
Sections were examined in a Tecnai 10 microscope (Fei Company, the Netherlands) 
and digital images are taken by Megaview III (SiS Company, Münster, Germany). 
 
Figure 10. Semiquantification by iEM. Six locations of the glomerulus were chosen according 
to a random systematic sampling procedure. 
Six locations per glomerulus (1–2 glomeruli, depending on material) were chosen with 
a random start at low magnification along the glomerular capillaries. Three images were 
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systematically taken from each location, including areas with or without foot process 
effacement (no sclerotic areas), giving a minimum of 18 images/specimen (Figure 10). 
Prints at a final magnification of 52 000× were examined and the number of gold 
markers (Au) counted in the podocytes, GBM and endothelial cells, respectively. The 
area of corresponding compartment is calculated by point counting, using a 1 × 1 cm 
square lattice (47), and expressed as µm2. Dividing the total number of gold particles by 
the area, give the concentration (Au/µm2).  
In order to distinguish between areas with and without FPE, the length of the GBM is 
measured and the number of slits/µm GBM calculated. Less than 1 slit/µm GBM is 
defined as FPE. 
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7.3 DATA COLLECTION AND STATISTICS 
 
The material prepared for iEM must be saved and embedded prospectively. Thus, such 
material can only be prepared if the biopsy is large enough to still allow a proper 
histopathologic examination. This means that for material from a certain disease we 
must both rely on the biopsy quality, the amount of material from the biopsy, and the 
general prevalence of the specific disease in our area. The relatively small number of 
cases from each specific disease can unfortunately be rather troublesome when it comes 
to statistics. 
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8 RESULTS
 
8.1 MAIN FINDINGS STUDY 1 
 
In normal renal tissue, IFL showed Dendrin in almost complete overlap with Nephrin 
in a linear pattern along the glomerular capillaries. With EM we could localize Dendrin 
close to the SD. 
Neither the staining pattern nor the intensity of Dendrin or ZO-1 differed between 
MCNS and controls using IFL, which was confirmed by iEM. No significant change in 
the total amount of Dendrin or ZO-1 was seen in MCNS compared to controls, neither 
in FPE areas nor without (Table 1). The proteins were redistributed from the SD in FPE 
areas to the podocyte cytoplasm. We did not find Dendrin to be translocated to the 
nucleus in neither PAN (Table 2) nor MCNS (data not published). 
 
Dendrin expression in the podocytes in human kidney 
 Slits/µm  Au/µm2  Au/slit  Percentage of 
Au on slits
Controls 
(n=5)
1,75 ± 0,26 1,24 ± 0,39 0,10 ± 0,03 36 ± 12 
MCNS, areas 
with FPE 
(n=5)
0,52 ± 0,11 0,94 ± 0,31 0,13 ± 0,09 17 ± 9* 
MCNS, areas 
without FPE 
(n=5)
1,64 ± 0,27 1,51 ± 0,96 0,18 ± 0,11 32 ± 4 
Table 1. Expression of Dendrin in controls and MCNS based on immunoelectron microscopy, 
gold particles/µm2 (Au/µm2). The data are presented as mean ± sd, * = p < 0.05 compared to 
controls. 
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Dendrin expression in the podocyte nucleus in rat 
 
Controls 1,18 ± 0,3 
PAN 1,34 ± 0,5 
Table 2. Expression of Dendrin in controls and MCNS based on immunoelectron microscopy, 
gold particles/µm2 (Au/µm2). The data are presented as mean ± sd. 
 
 
 
8.2 MAIN FINDINGS STUDY 2 
 
With iEM we localized Neph1 mainly to the SD in normal human, rat and mice kidney. 
Double iEM staining of Neph1 and Nephrin showed the proteins in close connection in 
the SD. This is, to our knowledge the first published EM image of the co-localization, 
and of Neph1 in human kidney (cover figure). 
By iEM semiquantification of biopsies from patients with perihilar FSGS and MCNS, 
we found a significantly reduced amount of Neph1 in the podocytes both in areas with 
and without FPE (Table 3). This reduction was also seen in the corresponding 
experimental models PAN and ADR (Table 4). Nephrin was also reduced in MCNS 
and PAN but unchanged in FSGS, both in areas with and without FPE (Table 4).  
Expression of Neph1 in podocytes in human kidney 
 
 Proteinuria
(g/24h) 
In podocyte 
(Au/µm2) 
FPE (Au/µm2) Non-FPE 
areas
(Au/µm2).
Controls 
(n=5) 
 0 1,5 ± 0,2 - - 
FSGS      
(n=5) 
1 g/24 h- 8 
g/24 h.  
  0,3 ± 0,1* 0,3 ± 0,2* 0,5 ± 0,3* 
MCNS
(n=5)
1g/l – 27g/24 h   0,5 ± 0,1* 0,5 ± 0,1* 0,5 ± 0,2*
Table 3. Expression of Neph1 in controls, FSGS and MCNS based on immunoelectron 
microscopy, gold particles/µm2 (Au/µm2). The data are presented as mean ± sd, * = p < 0.05 
compared to controls. 
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Summary of Neph1 findings 
 Neph1 Nephrin 
FSGS ↓ →
FSGS, FPE ↓ →
FSGS, Non FPE ↓ →
MCNS ↓ ↓
MCNS, FPE ↓ ↓
MCNS, Non FPE ↓ ↓
ADR, Day 7 ↓ →
ADR, Day 7, FPE ↓ →
ADR, Day 7, Non FPE ↓ →
ADR, Day 14 ↓  ↓ 
ADR, Day 14, FPE ↓  → 
ADR, Day 14, Non FPE ↓  → 
PAN, Day 2 ↓ ↓*
PAN, Day 2, FPE → ↓*
PAN, Day 2, Non FPE ↓ ↓*
PAN, Day 4 ↓ ↓*
PAN, Day 4, FPE ↓ ↓*
PAN, Day 4, non FPE ↓ ↓*
Table 4. Summary of findings based on immunoelectron microscopy. 
Notes: ↓ = significantly reduced (p < 0,05), → = no change compared to controls. 
*= Previously published (40). 
 
 
 33 
 
9 DISCUSSION
 
 
9.1 REFLECTIONS ON METHODS AND RESULTS 
9.1.1 Strengths/ Weaknesses of methods 
 
When studying protein expression in the filtration barrier, EM has the great advantage 
over light microscopy that it can be used to distinguish between areas with and 
without FPE. This means that the amount of protein can be evaluated in normal and 
effaced areas, respectively. 
The iEM technique that we have developed to semiquantify the expression of proteins 
is robust and well established at our department. However, due to the limited amount of 
specially embedded material there are sometimes statistical difficulties, as mentioned 
before.  
The experimental models of PAN and ADR have great advantages when evaluating 
changes in protein expression in relation to proteinuria and FPE. Though, we are aware 
of the caution that needs to be held against these models as representations of human 
glomerular diseases. Mainly because the toxic injury of the podocytes in these 
experimental models is both nonspecific and acute which affect the molecular 
composition of the filtration barrier differently than in the slow chronic progression of 
MCNS and FSGS (41, 48). 
 
9.1.2 Study 1 
 
With no change in the total amount of Dendrin or ZO-1 neither in areas with nor 
without FPE, the proteins are probably being redistributed from the SD to the podocyte 
cytoplasm, secondary to FPE. This pattern differs from our results on Nephrin and 
Neph1 in MCNS, which both are reduced in areas with FPE as well as in areas without, 
and therefore would be more probable key players in the processes behind FPE.
 
Recent years studies of Dendrin have focused on the proteins pro-apoptotic signaling 
properties, and the fact that it seems to accumulate in the podocyte nucleus in response 
to glomerular injury. 
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In 2011 Asanuma K et al (49) showed an accumulation of Dendrin in podocyte nuclei 
in ADR mice and in patients with FSGS, MN and Lupus Nephritis. In line with our 
results, they did not however, find nuclear Dendrin in MCNS patients.
Shankland, Mundel and colleagues have suggested that podocyte apoptosis causes 
podocyte loss from the GBM and leads to glomerulosclerosis in human glomerulopathy 
(3, 50). Asanuma K et al proposed that the relocation of Dendrin to the podocyte 
nucleus could serve as a marker of disease activity and prediction of progression to 
glomerulosclerosis in biopsy material. Kodama F et al demonstrated a similar 
translocation of Dendrin to the podocyte nuclei in patients with lgA nephropathy 
(IgAN). They concluded that this translocation enhances podocyte apoptosis in 
acute glomerular injury and leads to podocytopenia in IgAN patients. (51). It would be 
interesting to continue our Dendrin study with lgA patients in order to examine these 
findings of nuclear translocation. 
 
 
9.1.3 Study 2 
 
The reduction of Neph1 in combination with unchanged amounts of Nephrin in FSGS, 
could indicate a dissociation of the proteins and a disturbance of the complex.
The published results on the Nephrin expression in acquired kidney diseases are rather 
conflicting. Patrakka et al. (52) found no change in Nephrin expression in FSGS, 
neither in mRNA levels or by immunohistochemistry. Koop et al. (53) have reported 
the direct opposite, a marked reduction of the Nephrin protein and an increase at 
mRNA level. This was, however, evaluated from immunohistochemistry and 
immunofluorescence, with light microscopy. Kim et al. (54) concluded that the 
expression pattern in proteinuric diseases varies according to the severity of glomerular 
damage. Also, despite many attempts to portrait a correlation between the expression of 
Nephrin in glomerular diseases and the degree of proteinuria, the results are highly 
inconsistent (55).  
No other studies than ours, on the expression of Neph1 in human glomerular disease, 
have yet been published. 
We aimed to expand the study of the Neph1- Nephrin complex to double and 
traditional immunofluorescence staining. Unfortunately, we did not have frozen biopsy 
material from FSGS patients in our bio bank of sufficient quality. This is a general 
problem with frozen material which, despite storage in a -70 degrees Celsius freezer, 
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tend to dehydrate.  The material is therefore both very difficult to cut and to incubate, 
and the result may not be entirely reliable as the antibodies could bind non-specifically. 
A further complication was that the Neph1 antibody did not bind paraffin embedded 
material despite numerous different protocols.  
We have indications of Neph1 reduction in congenital nephrosis of the Finnish type. 
But with only two cases available for iEM, we did not include these data in the article.  
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6   THE POTENTIAL ROLE OF DENDRIN AND NEPH1 
IN THE FILTRATION BARRIER
When podocytes are injured they retract or extend their foot processes, detach from the 
GBM, or die (56, 57). Thus, the frequency of slit diaphragms is reduced, which results 
in impaired glomerular filtration with proteinuria as a result. 
Dendrin is localized to the SD where it binds Nephrin and CD2AP - an adaptor protein 
that can repress pro-apoptotic TGF-β signaling (58). Nephrin also binds Neph1 and 
Podocin in a transmembrane receptor complex, which interacts with actin associated 
proteins, for example CD2AP, ZO-1 and α-actinin-4. Loss of any of the proteins of the 
complex leads to proteinuria and FPE as studied in gene targeted mice (8, 12, 23, 59). 
Protamine sulphate (PS) perfusion of rodent kidneys is an animal model that results in 
immediate FPE which can be reversed by heparin sulphate (60). The knowledge about 
the trigger behind the actin transformation dynamics is very limited but it has been 
shown that the Neph1-Nephrin complex is phosphorylated following PS perfusion (61), 
and that the actin associated protein Cofilin-1, regulated by the complex, is needed for 
the reconstruction of the cytoskeleton following this injury (62). 
Complete balance and function of both structural and signaling proteins is clearly 
required to maintain the morphology of the foot processes, which are crucial to the 
function of the filtration barrier. However, the intricately of the proteins interplay with 
the cytoskeleton to maintain the structure and remodel it after podocyte injury is far 
from understood. 
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7  CLINICAL SIGNIFICANCE 
 
The main purpose of this project was to increase the understanding of the kidney filtration 
barrier and the role of structural glomerular proteins in the normal kidney and in acquired, 
proteinuric diseases. Increased knowledge about the mechanisms behind proteinuria and 
foot process effacement and the identification of the proteins involved may sharpen our 
diagnostic tools in the diagnosis of kidney biopsies. The specific proteins could, for 
example, ideally, be measured in urine and either serve as markers of disease activity  or 
maybe be used for differential diagnosis between FSGS and MCNS. Glomerular diseases 
may be better classified or sub-classified based on specific, individual protein expression 
or expression pattern and more directed therapies and thereby less harmful, may be 
possible in the future. 
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8  UNPUBLISHED RESULTS AND POSSIBLE FUTURE 
STUDIES
 
The most desirable trail to follow in order to find important proteins in glomerular 
disease would be transcriptome methods to identify up-and down regulated genes in 
biopsy material. Then continue with studies on knock down zebra fish, an experimental 
model that is both inexpensive, easy to breed and quickly examined. The knock down 
effect on the glomerular filtration barrier could be observed by EM and it can also be 
evaluated whether the zebra fish get proteinuria as a result of the knock down or not. 
These methods would hint which proteins that would be candidates to further study on 
human material using light and electron microscopy. 
Unfortunately the material from biopsy material is very limited, as mentioned before, 
which complicates transcriptome studies. Also, not all proteins work in the zebra fish 
experimental model. 
Another way to find new proteins specifically expressed in the glomerulus is through 
Human Protein Atlas, order as oligo products and run on PCR and agarose gel. This 
way we singled out the protein Prex2 as expressed solitary in the glomerular fraction. 
After western blot, the antibody was tested on paraffin embedded material and for 
electron microscopy and protocols were formulated. With iEM, Prex2 could be 
localized to the cytoplasm of the podocyte foot processes. It has not yet been studied in 
glomerular disease. A zebra fish knock down has been discussed. 
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